Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Trial Profile

Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2013

At a glance

  • Drugs Bendamustine (Primary) ; Dasatinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 20 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 24 Apr 2009 Planned number of patients changed from 48 to 60 as reported by ClinicalTrials.gov.
    • 24 Apr 2009 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top